Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Prospective Study "GFM-DACORAL-DLI" ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

NCT04857645 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT04857645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04857645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Prospective Study "GFM-DACORAL-DLI" ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 2
Overall status
Completed
Start date
June 22, 2021
Completion date
April 22, 2025
Enrollment
57 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mds